Eledon Pharmaceuticals (ELDN) Assets Average (2014 - 2026)

Eledon Pharmaceuticals' Assets Average history runs 13 years deep, the most recent figure standing at $157.8 million for Q1 2026.

• Quarterly Assets Average fell 6.8% year-over-year to $157.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157.8 million (down 6.8% YoY) and the FY2025 annual result came in at $173.2 million, up 30.0% from the prior year.
• Assets Average was $157.8 million for Q1 2026 at Eledon Pharmaceuticals, up from $149.4 million in the prior quarter.
• Across five years, Assets Average topped out at $169.4 million in Q1 2025 and bottomed at $84.9 million in Q1 2024.
• A 5-year average of $128.8 million and a median of $137.4 million in 2025 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average plunged 47.25% — and 2025, when it surged 99.38%.
• Eledon Pharmaceuticals' Assets Average stood at $121.2 million in 2022, then dropped by 23.62% to $92.6 million in 2023, then surged by 57.71% to $146.0 million in 2024, then gained by 2.36% to $149.4 million in 2025, then gained by 5.62% to $157.8 million in 2026.
• Business Quant data shows ELDN's Assets Average at $157.8 million in Q1 2026, $149.4 million in Q4 2025, and $137.4 million in Q3 2025.